BioNTech SE (BNTX)
96.90
+0.05
(+0.05%)
USD |
NASDAQ |
Oct 02, 16:00
96.90
0.00 (0.00%)
After-Hours: 20:00
BioNTech Enterprise Value : 7.809B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 7.809B |
| October 01, 2026 | 7.796B |
| September 30, 2026 | 8.161B |
| September 29, 2026 | 8.228B |
| September 28, 2026 | 8.357B |
| September 25, 2026 | 8.216B |
| September 24, 2026 | 8.402B |
| September 23, 2026 | 8.201B |
| September 22, 2026 | 8.806B |
| September 21, 2026 | 8.085B |
| September 18, 2026 | 7.598B |
| September 17, 2026 | 8.251B |
| September 16, 2026 | 7.540B |
| September 15, 2026 | 7.756B |
| September 14, 2026 | 8.301B |
| September 11, 2026 | 7.766B |
| September 10, 2026 | 7.683B |
| September 09, 2026 | 8.118B |
| September 08, 2026 | 8.251B |
| September 04, 2026 | 9.532B |
| September 03, 2026 | 9.311B |
| September 02, 2026 | 9.545B |
| September 01, 2026 | 9.076B |
| August 31, 2026 | 8.992B |
| August 28, 2026 | 9.109B |
| Date | Value |
|---|---|
| August 27, 2026 | 11.45B |
| August 26, 2026 | 11.74B |
| August 25, 2026 | 12.12B |
| August 24, 2026 | 11.81B |
| August 21, 2026 | 12.75B |
| August 20, 2026 | 11.32B |
| August 19, 2026 | 11.88B |
| August 18, 2026 | 6.766B |
| August 17, 2026 | 6.478B |
| August 14, 2026 | 6.852B |
| August 13, 2026 | 6.608B |
| August 12, 2026 | 6.764B |
| August 11, 2026 | 6.779B |
| August 10, 2026 | 6.779B |
| August 07, 2026 | 6.998B |
| August 06, 2026 | 6.375B |
| August 05, 2026 | 6.623B |
| August 04, 2026 | 6.415B |
| August 03, 2026 | 6.641B |
| July 31, 2026 | 6.221B |
| July 30, 2026 | 6.792B |
| July 29, 2026 | 6.817B |
| July 28, 2026 | 6.691B |
| July 27, 2026 | 6.349B |
| July 24, 2026 | 5.907B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 71.96B |
| Biodexa Pharmaceuticals Plc | -- |
| Mereo BioPharma Group Plc | 31.54M |
| NuCana Plc | -20.30M |
| MediGene AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -954.35M |
| Revenue (Quarterly) | 122.78M |
| Total Expenses (Quarterly) | 1.077B |
| EPS Diluted (Quarterly) | -3.799 |
| Gross Profit Margin (Quarterly) | -169.3% |
| Profit Margin (Quarterly) | -777.3% |
| Earnings Yield | -8.10% |
| Normalized Earnings Yield | -4.421 |